Aspirin and NSAIDs for the prevention of colorectal cancer - PubMed (original) (raw)

Review

Aspirin and NSAIDs for the prevention of colorectal cancer

John A Baron. Recent Results Cancer Res. 2009.

Abstract

With few exceptions, epidemiological studies have found that individuals who take nonsteroidal antiinflammatory drugs (NSAIDs) have a reduced risk of colorectal adenomas and carcinoma. Similarly, randomized studies in patients with familial adenomatous polyposis have uniformly found that NSAIDs can lead to polyp regression and prevention of new polyps, and trials in patients with sporadic adenomas document that aspirin reduces the risk of adenoma recurrence. Together these data provide convincing evidence for the chemopreventive efficacy ofNSAIDs in the large bowel.

PubMed Disclaimer

Similar articles

• Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review.
  Asano TK, McLeod RS. Asano TK, et al. Dis Colon Rectum. 2004 May;47(5):665-73. doi: 10.1007/s10350-003-0111-9. Epub 2004 Apr 2. Dis Colon Rectum. 2004. PMID: 15054679 Review.
• Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas.
  Huls G, Koornstra JJ, Kleibeuker JH. Huls G, et al. Lancet. 2003 Jul 19;362(9379):230-2. doi: 10.1016/s0140-6736(03)13915-3. Lancet. 2003. PMID: 12885487 Review.
• Nonsteroidal anti-inflammatory drugs and cancer prevention.
  Baron JA, Sandler RS. Baron JA, et al. Annu Rev Med. 2000;51:511-23. doi: 10.1146/annurev.med.51.1.511. Annu Rev Med. 2000. PMID: 10774479 Review.
• Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
  Asano TK, McLeod RS. Asano TK, et al. Cochrane Database Syst Rev. 2004;2004(2):CD004079. doi: 10.1002/14651858.CD004079.pub2. Cochrane Database Syst Rev. 2004. PMID: 15106236 Free PMC article. Review.
• Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
  Sandler RS. Sandler RS. Important Adv Oncol. 1996:123-37. Important Adv Oncol. 1996. PMID: 8791132 Review.

Cited by

• Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.
  Wang B, Wu L, Chen J, Dong L, Chen C, Wen Z, Hu J, Fleming I, Wang DW. Wang B, et al. Signal Transduct Target Ther. 2021 Feb 26;6(1):94. doi: 10.1038/s41392-020-00443-w. Signal Transduct Target Ther. 2021. PMID: 33637672 Free PMC article. Review.
• The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.
  Lin Y, Bai L, Chen W, Xu S. Lin Y, et al. Expert Opin Ther Targets. 2010 Jan;14(1):45-55. doi: 10.1517/14728220903431069. Expert Opin Ther Targets. 2010. PMID: 20001209 Free PMC article. Review.
• The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.
  Xie G, Nie T, Mackenzie GG, Sun Y, Huang L, Ouyang N, Alston N, Zhu C, Murray OT, Constantinides PP, Kopelovich L, Rigas B. Xie G, et al. Br J Pharmacol. 2012 Apr;165(7):2152-66. doi: 10.1111/j.1476-5381.2011.01705.x. Br J Pharmacol. 2012. PMID: 21955327 Free PMC article.
• Genetic variation in inflammatory pathways is related to colorectal cancer survival.
  Coghill AE, Newcomb PA, Poole EM, Hutter CM, Makar KW, Duggan D, Potter JD, Ulrich CM. Coghill AE, et al. Clin Cancer Res. 2011 Nov 15;17(22):7139-47. doi: 10.1158/1078-0432.CCR-11-1134. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976545 Free PMC article.
• Nonsteroidal anti-inflammatory drug sulindac sulfide suppresses structural protein Nesprin-2 expression in colorectal cancer cells.
  Liggett JL, Choi CK, Donnell RL, Kihm KD, Kim JS, Min KW, Noegel AA, Baek SJ. Liggett JL, et al. Biochim Biophys Acta. 2014 Jan;1840(1):322-31. doi: 10.1016/j.bbagen.2013.09.032. Epub 2013 Sep 27. Biochim Biophys Acta. 2014. PMID: 24080406 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information